From pig organs to artificial kidneys, Dr Reddy tracks a field in motion

Science finally dares to outpace the wait: As global demand for dialysis outstrips supply, bold experiments in genetics and engineering offer a rare kind of hope

SPOKANE

For 17 years, Dr Vijayakumar Reddy has watched patients live their lives in four‑hour slices. As a kidney specialist at Providence Medical Group, he sees the toll of end‑stage kidney disease up close: People tethered to a dialysis machine three times a week, every week, often for the rest of their lives unless a donor kidney appears.

Now, Dr Reddy is following a scientific revolution that could one day loosen those tethers. Across major research centers, including Harvard and New York University, scientists are pursuing a bold idea: Using animal organs to save human lives. The process, known as xenotransplantation, involves editing pig organs so the human body can accept them. It is no longer the stuff of science fiction.

Using CRISPR, a gene‑editing tool often described as molecular scissors, researchers have removed dangerous pig viruses and added human genes that help the body recognize the organ as its own.

In early 2024, surgeons at Massachusetts General Hospital reached a milestone when they transplanted a modified pig kidney into a living patient. It was the culmination of decades of work that began in the 1960s, when early attempts at cross‑species transplants failed quickly and often dramatically.

For years, the field was dismissed as fringe science. But advances in immunology, gene editing and organ preservation have pushed xenotransplantation from speculation into a serious medical frontier. Last year, a pig kidney functioned inside a human body for six months. Tim Andrews, 67, lived for 271 days with a gene‑edited pig kidney before his body eventually rejected it.

Medical journals called the moment a turning point. For doctors like Dr Reddy, it offered a glimpse of a future in which patients are not left waiting for organs that never come. “There are simply not enough human kidneys to go around,” he says. “If this technology succeeds, it will be one of the greatest breakthroughs in treating kidney failure. It’s a gift to humanity.”

The urgency is real. Kidney disease affects more than 800 million people worldwide, according to global nephrology estimates. In the United States alone, more than 90,000 people are waiting for a kidney transplant, far more than for any other organ. Yet only about 25,000 kidney transplants are performed each year. The math has never worked.

That is why researchers are pursuing multiple paths at once. While xenotransplantation aims to expand the supply of organs, another line of innovation seeks to eliminate the need for traditional dialysis altogether.

Dr Reddy believes artificial intelligence may soon play a role, particularly in dialysis. “A lot of energy is going to new treatment methods, and I can see AI having a role in dialysis in the future because it’s a treatment that is algorithmic,” he says. “This will certainly boost our capacity to handle more patients, which means more access to dialysis for more people.”

The need is vast. Globally, fewer than half of the people who require dialysis receive it. In parts of Africa, the proportion is far lower. Millions die each year simply because they cannot access treatment. Even in wealthier countries, dialysis centers are strained, and rural patients often travel long distances for care.

Dr Reddy hopes the next wave of technology will help doctors detect kidney disease long before dialysis or transplants are needed. Ultimately, he believes AI could shift the focus from costly treatment to early prevention. “AI can play a part in early screening by arresting kidney cases before they reach the end stage, so we can move from expensive treatment to life‑saving prevention,” he says.

Parallel to these biological breakthroughs, Dr Reddy is tracking another engineering feat that aims to shrink the entire dialysis clinic into something a person could carry, or even have implanted. The Kidney Project, a national research effort led by the University of California, San Francisco, is developing a small, implantable artificial kidney.

About the size of a coffee cup, the device uses tiny silicon filters and engineered human cells to clean the blood. It is designed to run on the patient’s own blood pressure, without electricity, tubes or weekly appointments. “The bioartificial kidney will also be a game changer for patients, although it has been quiet for a while,” Dr Reddy notes.

The idea of an artificial kidney has circulated for decades, but only recently have materials science and micro‑engineering advanced enough to make it plausible. Silicon membranes can now filter blood with extraordinary precision. Lab‑grown kidney cells can mimic some of the organ’s natural functions. If the device succeeds in human trials, it could free millions from the grueling routine of dialysis.

For now, Dr Reddy continues to care for patients who measure their lives in hours spent beside a machine. But he believes that, soon enough, the story of kidney disease may be rewritten, by science, by technology and by the determination of the people working to change what has long felt unchangeable.

news@thespokanetimes.com